Pfizer, one of the largest pharmaceutical companies in the world, and a long-time researcher of Alzheimer’s, Parkinson’s and other Neurodegenerative Disease drugs has halted all new research in this particular Neuroscience field. This announcement has come after close to two decades and over $55 Billion dollars of research has produced only three FDA approved medications with minimal effect. Current estimates are that in 60% of Alzheimer’s patients, these drugs are able to delay symptoms about only about six months to a year.
As you can see in this article from Reuters, Pfizer’s reasoning is to shift resources to other parts of their portfolio. The truth may be that they and other drug companies have realized that a single drug is not the answer to the Alzheimer’s problem. New research has proven that there are many factors leading toward Cognitive Decline and Alzheimer’s Disease, and only a multi-modal treatment approach can halt or even reverse the processes that lead to Cognitive Decline and Alzheimer’s Disease and the symptoms associated.
The good news is that our ReConnect Program is based on scientifically validated programs to reverse the processes that lead to Cognitive Decline, and does not involve the use of any of the above drugs. You can learn more about that here.
This statement from Pfizer is a huge blow to the mono-therapy drug world and a shift toward comprehensive, multi-modal treatment for Chronic Disease including Alzheimer’s. Click here to learn more about our programs to improve Brain Function and reduce symptoms associated with Cognitive Decline
Update: 7/2018 – We recently launched the reconnect program. The ReConnect Program is based off the framework and fundamentals of The Bredesen Protocol® with variations based upon our clinical experience of improving the brain function of over 10,000 individuals. To learn more visit our cognitive decline page.